W
Walter M. Stadler
Researcher at University of Chicago
Publications - 513
Citations - 37554
Walter M. Stadler is an academic researcher from University of Chicago. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 88, co-authored 494 publications receiving 34323 citations. Previous affiliations of Walter M. Stadler include Cleveland Clinic & Northwestern University.
Papers
More filters
Journal ArticleDOI
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.
Toni K. Choueiri,Mayer Fishman,Bernard Escudier,David F. McDermott,Charles G. Drake,Harriet M. Kluger,Walter M. Stadler,Jose Luis Perez-Gracia,Douglas G. McNeel,Brendan D. Curti,Michael R. Harrison,Elizabeth R. Plimack,Leonard Joseph Appleman,Lawrence Fong,Laurence Albiges,Lewis J. Cohen,Tina C. Young,Scott D. Chasalow,Petra Ross-Macdonald,Shivani Srivastava,Maria Jure-Kunkel,John F. Kurland,Jason S. Simon,Mario Sznol +23 more
TL;DR: Immunomodulatory effects of PD-1 inhibition were demonstrated through multiple lines of evidence across nivolumab doses in a hypothesis-generating prospective mRCC trial of previously treated patients with metastatic renal cell carcinoma.
Journal ArticleDOI
Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 Status
Walter M. Stadler,Seth P. Lerner,Susan Groshen,John P. Stein,Shan Rong Shi,Derek Raghavan,David Esrig,Gary D. Steinberg,Darien Wood,Laurence Klotz,Craig Hall,Donald G. Skinner,Richard J. Cote +12 more
TL;DR: Neither the prognostic value of p53 nor the benefit of MVAC chemotherapy in patients with p53-positive tumors was confirmed, but the high patient refusal rate, lower than expected event rate, and failures to receive assigned therapy severely compromised study power.
Journal ArticleDOI
Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)
Matthew R. Smith,Susan Halabi,Charles J. Ryan,Arif Hussain,Nicholas A. Vogelzang,Walter M. Stadler,Ralph J. Hauke,J. Paul Monk,Philip J. Saylor,Nirmala Bhoopalam,Fred Saad,Ben L. Sanford,W. Kevin Kelly,Michael J. Morris,Eric J. Small +14 more
TL;DR: In men with castration-sensitive prostate cancer and bone metastases, early treatment with zoledronic acid was not associated with lower risk for SREs and overall survival was similar between the groups.
Journal ArticleDOI
Flavopiridol, A Novel Cyclin-Dependent Kinase Inhibitor, in Metastatic Renal Cancer: A University of Chicago Phase II Consortium Study
Walter M. Stadler,Nicholas J. Vogelzang,Robert J Amato,Jeffery Sosman,David A. Taber,David Liebowitz,E. E. Vokes +6 more
TL;DR: Flavopiridol is ineffective in metastatic renal cancer, at the dose and schedule administered in this trial, and the most common toxicities were asthenia and diarrhea.
Journal ArticleDOI
Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Roberto Pili,Michael Häggman,Walter M. Stadler,Jeffrey R. Gingrich,Vasileios J. Assikis,Anders Björk,Orjan Nordle,Göran Forsberg,Michael A. Carducci,Andrew J. Armstrong +9 more
TL;DR: TASQ significantly slowed progression and improved PFS in patients with metastatic CRPC with an acceptable AE profile, and the impact on PSA kinetics was less pronounced.